Recruiting OBSERVATIONAL NCT05282108

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia (CARCML)

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia; a Multicenter, Observational Study

Sponsor: Hikma Pharmaceuticals LLC

Conditions Chronic Myeloid Leukemia

Interventions Carcemia Glivec

Updated 6 times since 2022 Last updated: Mar 23, 2025 Started: Jul 20, 2022 Primary completion: Aug 31, 2026 Completion: Nov 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05282108, this observational or N/A phase trial focuses on Chronic Myeloid Leukemia and remains actively recruiting participants. Sponsored by Hikma Pharmaceuticals LLC, it has been updated 6 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Apr 2025 — Present [monthly]

Recruiting
Sep 2024 — Apr 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Oct 2023 — Jul 2024 [monthly]

Recruiting
Apr 2023 — Oct 2023 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Apr 2022 — Apr 2023 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hikma Pharmaceuticals LLC

Data source: Hikma Pharmaceuticals LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt
• Tanta, Egypt